1. Introduction
Cancer, characterized by the uncontrolled proliferation of abnormal cells, constitutes a leading global health burden and one of the primary causes of mortality. Globally, in 2022, an estimated 20 million new cancer cases were diagnosed, resulting in 9.7 million deaths [
1]. This corresponds to approximately one in six deaths worldwide being attributable to cancer [
2]. Furthermore, epidemiological data suggest that approximately 1 in 5 individuals will develop cancer during their lifetime, with a disproportionately higher mortality rate among women, where 1 in 12 is expected to succumb to the disease [
1]. In Türkiye, the impact of cancer is also substantial. According to the Republic of Türkiye Ministry of Health General Directorate of Public Health [
3], approximately 223.087 new cancer cases were diagnosed in 2019, and malignant and benign neoplasms contributed to one in five deaths in the country during the same year [
4]. Hematologic malignancies represent a significant subset of cancer diagnoses, with over 1 million new cases estimated to be reported globally each year [
1,
5]. In Türkiye, lymphoid and hematopoietic malignant tumors accounted for 1.16% of all deaths in 2023 [
6].
Studies consistently demonstrate that cancer patients frequently experience significant psychological distress following diagnosis, including depression, anxiety, and stress [
7]. Similar findings have also been reported among patients with hematologic cancers. For example, Clinton-McHarg et al. [
8] reported that 27% of patients were diagnosed with anxiety and 17% with depression, with 12% exhibiting comorbid anxiety and depression. Similarly, Bergerot et al. [
9] found that 50% of hematologic cancer patients reported significant distress, 47.1% experienced anxiety, and 26% experienced depression. Abuelgasim et al. [
10] further corroborated these findings, reporting a 46.5% prevalence of depression, 22.3% prevalence of anxiety, and 18.1% prevalence of comorbid anxiety and depression in patients with hematologic malignancies.
Patients with hematologic malignancies consistently experience diminished quality of life across multiple domains. Specifically, studies have demonstrated that these individuals report lower physical, psychological, emotional, and social well-being compared to the general population [
11]. Furthermore, psychological distress, including depression, anxiety, and stress, significantly correlates with reduced quality of life in this patient population [
12]. Research has also suggested that the impact of cancer treatment extends beyond immediate medical concerns because patients frequently experience a constellation of long-term symptoms, including pain, sleep disturbances, fatigue, and gastrointestinal issues, along with treatment-related financial burden, which in turn can adversely affect mental health [
13]. Untreated depression following a cancer diagnosis has been linked to decreased treatment adherence and poor survival outcomes [
14]. Researchers have also identified specific relationships between psychological symptoms and quality of life metrics in the hematologic cancer patient population. For example, Nakano et al. [
15] found that anxiety levels correlated with age, nausea, and cognitive function, whereas depression showed a significant association with insomnia. Their research further demonstrated that patients experiencing anxiety and depression exhibited lower physical functioning scores and reported more severe symptoms on standardized quality of life assessments.
Mental health protection in cancer patients is crucial, not only for optimizing treatment outcomes and quality of life but also for reducing health care costs at both systemic and individual levels [
16]. The early identification and management of mental health concerns in cancer patients and their families necessitates the use of validated, reliable instruments for measuring depression, anxiety, and stress symptoms. The Depression Anxiety Stress Scales (DASS) is one of the most commonly used instruments to assess negative emotional states in oncology settings. The DASS were designed as a composite measure of negative emotional states, specifically targeting the dimensions of depression, anxiety, and stress. The full DASS consists of 42 items (DASS-42), distributed equally across three scales, each containing 14 items. A shorter version, the DASS-21, includes 21 items with 7 items per scale. The DASS-21 demonstrates psychometric properties comparable to the DASS-42 and is generally preferred in research settings where participant time is limited [
17,
18]. The depression subscale assesses the presence and severity of depressive symptoms, including self-deprecation, lack of interest in daily activities, inertia, hopelessness, dysphoria, devaluation of life, and anhedonia. The anxiety subscale assesses the presence and severity of anxiety symptoms related to the subjective experience of anxious affect, skeletal musculature effects, situational anxiety, and autonomic arousal. Finally, the stress subscale assesses the presence and severity of stress symptoms, including overreactivity, agitation, nervous arousal, irritability, impatience, and difficulty relaxing [
17,
18]. Notably, although stress can be conceptualized theoretically as either a stimulus or a response, the DASS stress subscale specifically adopts a response-based framework [
19].
Accurate measurement of psychological distress is paramount in cancer research and clinical practice. Although the DASS is not a diagnostic instrument, it serves as a valuable screening and research tool for identifying individuals at risk for psychopathology. However, the construct validity of the DASS remains complex, with studies yielding inconsistent findings across diverse populations. Specifically, researchers have explored various factor structures, including the original three-factor model, a single-factor model, two-factor models, and a bifactor model. Although the three-factor structure is frequently supported [
19,
20,
21,
22,
23,
24,
25], some studies suggest that a single-factor [
26] or bifactor model [
27,
28,
29] better captures the underlying dimensions of distress, and some studies find that both the three-factor and bifactor models are adequate [
30,
31]. These discrepancies may arise from several sources, including variations in sample demographics (e.g., age, cultural background), differences in the specific DASS versions used (e.g., DASS-21 vs. DASS-42), variations in the statistical methods employed for factor analysis, and the inherent complexity of the construct of psychological distress itself, which highlight the need for further research to determine the most appropriate factor structure for diverse populations. In cancer populations, the measurement of psychological distress is further complicated by symptoms such as pain, fatigue, mortality concerns, and treatment-related side effects, which can overlap with symptoms of depression and anxiety [
32]. Consequently, psychological assessment tools validated in general populations may not perform equivalently in oncology settings.
Hematologic malignancies represent a significant proportion of cancer diagnoses globally, with increasing prevalence particularly in developed nations. This trend has elevated these cancers to a critical public health concern with long-term societal and economic consequences [
12]. The pattern is similarly reflected in Türkiye, where hematologic cancers rank among the most frequently diagnosed malignancies [
3]. Understanding the prevalence of psychological distress among hematologic cancer patients is fundamental to health care delivery and service development. Such epidemiological data also enable both the implementation of appropriate interventions and the identification of at-risk individuals requiring targeted support [
8]. Despite significant medical advancements that have markedly reduced mortality rates in recent years, hematologic malignancies continue to evoke significant fear and uncertainty in affected individuals [
9]. This psychological burden places patients at elevated risk for emotional distress, emphasizing the necessity for early detection and intervention strategies [
33]. Given the strong psychometric properties of the DASS across psychiatric, medical, and community samples; its theoretically and empirically driven development; its capacity to differentiate among various dimensions of psychological distress; and its utility as a routine clinical outcome measure, the DASS may serve as a valuable instrument for researchers and clinicians working with hematologic cancer patients [
34].
A systematic review of literature examining the psychometric properties of both DASS-42 and DASS-21 has identified several significant limitations [
31,
35]. Research has predominantly focused on DASS-21 psychometric properties, with limited investigation of DASS-42 validity and reliability in clinical populations, particularly cancer patients [
19]. Notably, the psychometric properties of either scale remain unexamined specifically within hematologic cancer populations. The generalizability of existing DASS validation studies is further limited by their predominant focus on Western populations, potentially overlooking crucial cultural variations in collectivist societies such as Türkiye. The cancer experience in Turkish society presents unique psychological challenges shaped by traditional family structures, social support systems, and cultural beliefs. Specific cultural practices, such as the perception of cancer as “bad news” and occasional withholding of diagnoses from patients, create distinct challenges for psychological assessment and intervention planning [
36]. This cultural context may influence both the manifestation and intensity of psychological distress symptoms, necessitating culturally sensitive assessment tools. The evaluation of DASS-42 and DASS-21 psychometric properties in Turkish hematologic cancer patients is therefore crucial for determining their effectiveness in measuring psychological distress within this specific cultural framework. Furthermore, most existing psychological assessment instruments were developed for general populations, failing to account for the unique symptomatology and experiences associated with hematologic cancers, including treatment-related fatigue, pain, and illness uncertainty. This limitation underscores the importance of validating these scales within specific clinical populations to ensure accurate assessment of psychological needs and appropriate intervention planning.
Turkish hematologic cancer patients face a particularly challenging treatment trajectory, characterized by prolonged and intensive therapies, frequent hospitalizations, and severe side effects that significantly compromise quality of life. Therefore, accurate assessment of their psychological status is crucial for developing culturally tailored and effective intervention programs. However, a significant gap exists in standardized, valid, and reliable measurement tools for psychological distress in this population within Türkiye, hindering both research and clinical practice. To our knowledge, no studies have examined the psychometric properties of the DASS-42 and DASS-21 in Turkish hematologic cancer patients. Addressing this gap is essential because investigating the psychometric properties of the DASS in this specific patient group will provide valuable insights for researchers and clinicians, enhancing their understanding of psychological needs and facilitating targeted intervention design. Consequently, the aim of this study is to examine the construct, convergent and discriminant validity, measurement invariance, and internal consistency and test–retest reliability of the DASS-42 and DASS-21 in Turkish hematologic cancer patients across three studies.
8. Discussion
In this study, we examined the validity and reliability of the DASS-42 and DASS-21 among hematologic cancer patients. We tested seven alternative models to assess the construct validity of the DASS-42 and DASS-21, and we found that both the theoretically proposed correlated three-factor structure and the bifactor structure provided a better fit to the data compared to the other competing models. However, the bifactor model demonstrated a slightly better fit to the data compared to the correlated three-factor structure. Model parameter estimates, including factor loadings and standard errors, were adequate for both models. These findings support the correlated three-factor structure that Lovibond and Lovibond [
18] proposed. The findings align with those of previous studies using the DASS-21 in both clinical and nonclinical samples, which have shown that the scale fits well with both the correlated three-factor structure and the bifactor model [
30,
31]. For example, the meta-confirmatory factor analysis by Yeung et al. [
31] demonstrated that both the correlated three-factor structure and the bifactor model provided a good fit to the DASS-21 data, although the bifactor model showed a slightly better fit. Consistently, in a study involving university students from eight countries, Zanon et al. [
30] found that both the correlated three-factor structure and the bifactor model provided a good fit to the DASS-21 data across all countries. Furthermore, the researchers reported that, based on model-based validity and reliability analyses, a significant portion of the systematic variance in DASS-21 depression, anxiety, and stress scores could be attributed to individual differences in the general psychological distress factor, suggesting that evaluations based solely on subscale scores may be misleading. Similarly, Lee et al. [
35] conducted a comprehensive systematic review of the psychometric properties of the DASS-21 and concluded that the bifactor model consistently demonstrated the strongest evidence of validity and reliability across clinical and nonclinical samples. Consistent with existing literature on the DASS-21, the present study supports its validity among cancer patients, extending its generalizability to hematologic cancer patients and confirming its utility alongside the DASS-42.
The bifactor model’s slightly better fit in the present study highlights the interconnected nature of depression, anxiety, and stress symptoms, which aligns with the theoretical foundation of the DASS. Although DASS-42 and DASS-21 were designed to maximally differentiate depression, anxiety, and stress symptoms based on a tripartite model of anxiety and depression, a lack of specificity may be expected in these 3 emotional states among hematologic cancer patients. Empirical studies have found that mood and anxiety disorder symptoms are very strongly correlated with each other among adults, and adults who are diagnosed with mood or anxiety disorders in their lifetime have an increased risk for subsequently developing the other disorder [
67,
68]. Tiller [
69] posited that depression and anxiety disorders exhibit commonality in terms of general, cognitive, emotional, psychological, and physical symptoms. It is also possible to see this overlap in the DASS-21 items. All 3 subscales of the DASS-21 assess negative affect (emotional stress) such as feelings of dysphoria and worthlessness in the depression subscale, anxious affect and situational anxiety in the anxiety subscale, and nervous arousal and irritability in the stress subscale [
17,
18]. Depression, anxiety, and stress symptoms often manifest themselves as changes in cognitive processes and behaviors [
70,
71]. For example, these changes were measured in the depression subscale with anhedonia (loss of interest or pleasure in daily activities) and inertia (feeling slowed down or lacking energy), which can also be related to anxiety and stress symptoms. The stress subscale includes items related to irritability, impatience, and overreaction, which can be associated with both anxiety and depression symptoms in adult individuals [
72]. Moreover, physiological responses to stressors can be triggered by anxiety (e.g., autonomic arousal, skeletal musculature effects) and stress (e.g., nervous arousal, agitation) symptoms, which in turn lead to increases in depressive symptoms [
73]. Given the interconnected nature of depression, anxiety, and stress symptoms in daily life, individuals can experience difficulty differentiating and separately conceptualizing these symptoms. This difficulty can occur because these symptoms often reflect a general psychological distress factor, as demonstrated by the bifactor model of DASS-42 and DASS-21 in hematologic cancer patients.
Multiple group confirmatory factor analyses revealed that both the DASS-42 and DASS-21 demonstrated configural, metric, and scalar invariance across gender for the correlated three-factor and bifactor model. These results align with prior research showing that the correlated three-factor model [
21,
22,
23,
26] and the bifactor model [
29] of the DASS-21 exhibit measurement invariance across gender in nonclinical samples. The current findings extend this evidence to the DASS-42 and DASS-21 in clinical samples, specifically hematologic cancer patients, confirming their configural, metric, and scalar invariance across gender. The configural invariance of the DASS-42 and DASS-21 suggests that women and men conceptualize depression, anxiety, stress, or general psychological distress similarly. In other words, the overall latent factor structure of the DASS-42 and DASS-21 (whether the correlated three-factor or bifactor model) remains consistent across women and men with hematologic cancer. The metric invariance further suggests that the strength of the relationship between each DASS item and its respective latent construct (depression, anxiety, stress, or general psychological distress) is comparable for women and men. In practical terms, this means that changes in the latent constructs are reflected in changes in observed DASS scores in a similar manner for both genders. The scalar invariance of both models across both versions indicates that individuals, regardless of gender, have the same expected response at the same absolute latent level of depression, anxiety, stress, or psychological distress. This suggests that male and female hematologic cancer patients interpret the response categories similarly, and any observed differences in item responses can be attributed solely to actual differences in latent factor means rather than measurement bias [
40,
42]. Because the observed gender differences in scores reflect actual differences in depression, anxiety, and stress levels rather than measurement artifacts, mean scores on the DASS-42 and DASS-21 subscales can be validly compared between male and female hematologic cancer patients [
40,
42].
We assessed the convergent and discriminant validity of the DASS-42 and DASS-21 by examining their correlations with measures of psychological well-being (e.g., happiness, well-being, life satisfaction) and similar constructs (e.g., depression, anxiety, stress). As expected, the DASS-42 and DASS-21 subscales demonstrated strong convergent and discriminant validity by exhibiting high positive correlations with measures of depression, anxiety, and stress and moderate to high negative correlations with measures of psychological well-being. These findings are consistent with previous research supporting the convergent and discriminant validity of DASS [
19,
20,
25,
29,
74]. For example, Bengwasan et al. [
20] demonstrated strong positive correlations between DASS-21 subscales and both PHQ-9 and GAD-7 scores, alongside moderate to high negative correlations with FS scores. Similarly, Lee and Kim [
29] found moderate to high positive correlations between DASS-21 subscales and PHQ-9, GAD-7, and PSS-10 scores. In the context of cancer patients, Soria-Reyes et al. [
19] observed moderate negative correlations between DASS-21 subscales and SWLS scores. Şahin et al. [
25] reported moderate to high negative correlations between DASS-21 subscales and SIHS scores in an adult sample. Moreover, results of Steiger’s z-test analyses comparing DASS-42 and DASS-21 revealed significant differences in only 3 out of 18 comparisons with criterion variables (PHQ-9, GAD-7, PSS-10, SWLS, FS, SIHS). However, 15 out of 18 comparisons (83.33%) were not significant, indicating that the strengths of correlations were generally statistically equivalent. In practical terms, these findings suggest that the DASS-21 subscales demonstrate very similar levels of convergent and discriminant validity to the DASS-42 subscales when related to measures of depression, anxiety, stress, and well-being indicators (life satisfaction, well-being, happiness). The shorter DASS-21 appears to capture the same validity relationships as the DASS-42 in most cases.
Test–retest reliability, item analysis, internal consistency, and floor and ceiling effect analyses also supported the reliability of the DASS-42 and DASS-21. Because test–retest reliability analyses show that the DASS-42 and DASS-21 depression, anxiety, and stress subscales exhibit good temporal stability over a 1-month interval and produce similar and relatively stable scores over time [
61,
63], these subscales can be used to examine differences in depression, anxiety, and stress scores across and within groups over time as well as to assess the effectiveness of treatments and interventions. Item analyses of the DASS-42 and DASS-21 revealed moderate to high corrected item–total correlations across the depression, anxiety, and stress subscales. These correlations indicate that individual item scores demonstrated strong associations with their respective subscale total scores, suggesting that items effectively discriminate between individuals with varying levels of depression, anxiety, and stress symptoms [
64,
65]. Cronbach’s alpha reliability values indicated strong internal consistency among the items of the DASS-42 and DASS-21 depression, anxiety, and stress subscales, with values ranging from high to very high, demonstrating that both scales exhibit strong reliability and are suitable for screening and research purposes [
43,
64,
65]. These findings align with previous research consistently demonstrating high reliability coefficients for both the DASS-42 and DASS-21 across diverse populations and contexts [
18,
19,
20,
23,
24,
29,
74].
Furthermore, we examined the item-scale convergent and discriminant validity of the DASS-42 and DASS-21 subscales using the method that Sinclair et al. [
62] proposed. The results indicated that 85.7% (12/14) of the DASS-42 depression subscale items, 71.4% (10/14) of the anxiety subscale items, and 78.6% (11/14) of the stress subscale items had stronger correlations with their respective subscales. For the DASS-21, 85.7% (6/7) of the depression subscale items, 57.1% (4/7) of the anxiety subscale items, and 71.4% (5/7) of the stress subscale items showed stronger correlations with their own subscales. These findings are consistent with Sinclair et al.’s [
62] results regarding DASS-21’s item-scale convergent and discriminant validity while extending the evidence to DASS-42. These findings also support Watson and Clark’s [
75] tripartite model of anxiety and depression, which conceptualizes depression, anxiety, and stress as interrelated but distinct constructs. Additionally, floor and ceiling effect analyses revealed that the percentage of participants scoring at the extreme ends was generally below the 15% threshold [
66], with the exception of the DASS-21 depression subscale. This general absence of floor and ceiling effects strengthens evidence for the reliability, content validity, and responsiveness of both the DASS-42 and DASS-21 subscales [
66].
8.1. Practical Implications
The results of this study have several practical implications for clinical practice and research with hematologic cancer patients. The results demonstrate that the DASS-42 and DASS-21 are reliable and valid instruments for assessing depression, anxiety, and stress levels in hematologic cancer patients, offering clinicians and researchers a valuable tool for patient assessment. Clinicians can use these scales to monitor changes in depression, anxiety, and stress levels over time, allowing them to track patient progress and adjust treatment plans accordingly. The bifactor model findings, which highlight the interconnected nature of depression, anxiety, and stress, suggest that clinicians should implement integrated treatment approaches rather than addressing these conditions in isolation. This interconnectedness supports the use of transdiagnostic interventions such as acceptance and commitment therapy or mindfulness-based cognitive therapy, which target underlying psychological mechanisms shared across these symptom domains. For medication management, these findings suggest psychiatrists should consider pharmacotherapies with broader effects across symptom domains rather than highly targeted medications for single conditions.
The measurement invariance of the DASS-42 and DASS-21 across gender suggests that these scales can be used to compare depression, anxiety, and stress levels between male and female hematologic cancer patients, facilitating the development of gender-sensitive intervention plans and implementation of targeted support strategies based on gender-specific needs. Furthermore, the scales demonstrate good test–retest reliability, making them suitable for use in treatment processes to monitor changes in symptoms of psychological distress throughout the course of cancer treatment and evaluate the effectiveness of intervention programs. The finding that the DASS-21 shows similar psychometric properties to the DASS-42 as a short form suggests that the shorter version may be preferred in time-constrained clinical settings or when patient fatigue is a significant factor, such as during chemotherapy sessions or presurgical evaluations. This is particularly relevant given the increased prevalence of fatigue in hematologic cancer patients, as previous studies [
76] have documented. Finally, the general absence of floor and ceiling effects in the scales suggests that they can be used to assess patients with varying levels of symptom severity, which is crucial for monitoring patients with both mild and severe symptoms. Overall, these validated instruments provide oncology teams with reliable tools to inform psychological intervention planning, evaluate treatment effectiveness, and tailor supportive care approaches to the unique needs of hematologic cancer patients throughout their treatment journey.
8.2. Limitations
This study has several limitations that should be considered when interpreting the findings. First, we collected the data from only two hospitals (Samsun Training and Research Hospital and Çanakkale Mehmet Akif Ersoy State Hospital), which limits the generalizability of the findings to all hematologic cancer patients in Türkiye. Additionally, the external validity of the findings is limited, not only because the hematologic cancer patients studied represent only a small minority of the global cancer patient population but also because the interpretation and expression of symptoms of depression, anxiety, and stress may vary significantly across different groups of cancer patients.
Although the DASS-42 and DASS-21 exhibit robust psychometric properties for assessing depression, anxiety, and stress, their scope is inherently limited in capturing the full spectrum of psychological distress that hematologic cancer patients experience. These instruments do not specifically assess cancer-related concerns such as fear of recurrence, existential distress, body image issues, or treatment-specific anxieties, which are often prominent in this population [
77]. Additionally, they do not measure other relevant mental health constructs, such as post-traumatic stress symptoms, complicated grief reactions, or adjustment disorders, which may be prevalent among cancer patients facing life-threatening illness [
78,
79]. Furthermore, these scales may not adequately capture culturally specific expressions of distress that could be significant in Turkish populations. Future research should consider supplementing DASS assessments with cancer-specific psychological measures to achieve a more comprehensive understanding of psychological functioning in hematologic cancer patients.
Another limitation pertains to the demographic variations within the sample, particularly regarding age, which ranged from 18 to 91 years across the studies. This wide age range introduces potential heterogeneity that may influence the interpretation of the results. For example, younger patients might experience distress related to disruptions in developmental milestones (e.g., education, career, family planning), whereas older patients might face distress tied to comorbidities, reduced physical resilience, or existential concerns about mortality. Such age-related differences could affect how depression, anxiety, and stress are experienced and reported on the DASS-42 and DASS-21, potentially affecting the scales’ sensitivity and specificity across age groups. Although the sample size was sufficient to support the psychometric analyses, the study did not explicitly examine age as a moderating factor, limiting our understanding of its influence on the scales’ performance. Future research should explore age-stratified analyses or measurement invariance testing across age groups to clarify these potential effects.
The reliance on self-report data collection tools introduces additional limitations, such as the potential for social desirability bias or recall bias to affect the research results. We also did not account for external factors (e.g., socioeconomic status, psychotropic medication use) that may influence symptom intensity and lead to systematic variation in item responses because these factors were not attributed to the DASS latent constructs. Although the large sample size likely mitigates the impact of these unmeasured factors [
40,
42], future research should explicitly include these variables in the study design to explore their potential influence on DASS scores. In addition, future research should investigate the predictive validity of the DASS-42 and DASS-21 by examining their ability to predict clinically relevant outcomes, such as treatment response, disease progression, or quality of life, over time. Researchers could also explore the predictive validity of specific factors related to depression, anxiety, and stress beyond the general stress factor using external criteria.